Literature DB >> 15331753

A naturally occurring variation in the proline-rich region does not attenuate human immunodeficiency virus type 1 nef function.

Elke Rücker1, Jan Münch, Steffen Wildum, Matthias Brenner, Jutta Eisemann, Leonid Margolis, Frank Kirchhoff.   

Abstract

We analyzed human immunodeficiency virus type 1 (HIV-1) Nef variants to further evaluate the functional relevance of the R71T substitution previously proposed to attenuate viral replication (Fackler et al., Curr. Biol. 11:1294-1299, 2001). Our results demonstrate that this variation in the proline-rich region does not significantly affect the functional activity of Nef or HIV-1 infectivity or replication. Copyright 2004 American Society for Microbiology

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15331753      PMCID： PMC514962          DOI： 10.1128/JVI.78.18.10197-10201.2004

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  28 in total

1.  A natural variability in the proline-rich motif of Nef modulates HIV-1 replication in primary T cells.

Authors:  O T Fackler; D Wolf; H O Weber; B Laffert; P D'Aloja; B Schuler-Thurner; R Geffin; K Saksela; M Geyer; B M Peterlin; G Schuler; A S Baur
Journal:  Curr Biol       Date:  2001-08-21       Impact factor: 10.834

2.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

3.  Nef enhances human immunodeficiency virus replication and responsiveness to interleukin-2 in human lymphoid tissue ex vivo.

Authors:  S Glushakova; J C Grivel; K Suryanarayana; P Meylan; J D Lifson; R Desrosiers; L Margolis
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

4.  Serine phosphorylation-independent downregulation of cell-surface CD4 by nef.

Authors:  J V Garcia; A D Miller
Journal:  Nature       Date:  1991-04-11       Impact factor: 49.962

5.  CD4 down-modulation by human immunodeficiency virus type 1 Nef correlates with the efficiency of viral replication and with CD4(+) T-cell depletion in human lymphoid tissue ex vivo.

Authors:  S Glushakova; J Münch; S Carl; T C Greenough; J L Sullivan; L Margolis; F Kirchhoff
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

6.  Nef-mediated downregulation of CD4 enhances human immunodeficiency virus type 1 replication in primary T lymphocytes.

Authors:  Christopher A Lundquist; Minoru Tobiume; Jing Zhou; Derya Unutmaz; Christopher Aiken
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

7.  Down-modulation of mature major histocompatibility complex class II and up-regulation of invariant chain cell surface expression are well-conserved functions of human and simian immunodeficiency virus nef alleles.

Authors:  Michael Schindler; Stephanie Würfl; Philippe Benaroch; Thomas C Greenough; Rod Daniels; Philippa Easterbrook; Matthias Brenner; Jan Münch; Frank Kirchhoff
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Nef enhances human immunodeficiency virus type 1 infectivity and replication independently of viral coreceptor tropism.

Authors:  Armin Papkalla; Jan Münch; Claas Otto; Frank Kirchhoff
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

9.  Enhanced CD4 down-modulation by late stage HIV-1 nef alleles is associated with increased Env incorporation and viral replication.

Authors:  Enrique R Argañaraz; Michael Schindler; Frank Kirchhoff; María J Cortes; Juan Lama
Journal:  J Biol Chem       Date:  2003-06-19       Impact factor: 5.157

10.  HIV-1 Nef intersects the macrophage CD40L signalling pathway to promote resting-cell infection.

Authors:  Simon Swingler; Beda Brichacek; Jean-Marc Jacque; Catherine Ulich; Jin Zhou; Mario Stevenson
Journal:  Nature       Date:  2003-07-10       Impact factor: 69.504
View more
  6 in total

1.  Expression of Nef downregulates CXCR4, the major coreceptor of human immunodeficiency virus, from the surfaces of target cells and thereby enhances resistance to superinfection.

Authors:  Stephanie Venzke; Nico Michel; Ina Allespach; Oliver T Fackler; Oliver T Keppler
Journal:  J Virol       Date:  2006-08-23       Impact factor: 5.103

2.  Primary human immunodeficiency virus type 1 nef alleles show major differences in pathogenicity in transgenic mice.

Authors:  Elena Priceputu; Zaher Hanna; Chunyan Hu; Marie-Chantal Simard; Patrick Vincent; Steffen Wildum; Michael Schindler; Frank Kirchhoff; Paul Jolicoeur
Journal:  J Virol       Date:  2007-02-21       Impact factor: 5.103

3.  Differential pathogenesis of primary CCR5-using human immunodeficiency virus type 1 isolates in ex vivo human lymphoid tissue.

Authors:  Ingrid Karlsson; Jean-Charles Grivel; Silvia Sihui Chen; Anders Karlsson; Jan Albert; Eva Maria Fenyö; Leonid B Margolis
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

4.  Nef-mediated enhancement of virion infectivity and stimulation of viral replication are fundamental properties of primate lentiviruses.

Authors:  Jan Münch; Devi Rajan; Michael Schindler; Anke Specht; Elke Rücker; Francis J Novembre; Eric Nerrienet; Michaela C Müller-Trutwin; Martine Peeters; Beatrice H Hahn; Frank Kirchhoff
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

5.  Association of Nef with p21-activated kinase 2 is dispensable for efficient human immunodeficiency virus type 1 replication and cytopathicity in ex vivo-infected human lymphoid tissue.

Authors:  Michael Schindler; Devi Rajan; Anke Specht; Carolin Ritter; Kati Pulkkinen; Kalle Saksela; Frank Kirchhoff
Journal:  J Virol       Date:  2007-09-19       Impact factor: 5.103

6.  Identification of a highly conserved valine-glycine-phenylalanine amino acid triplet required for HIV-1 Nef function.

Authors:  Pieter J Meuwissen; Bettina Stolp; Veronica Iannucci; Jolien Vermeire; Evelien Naessens; Kalle Saksela; Matthias Geyer; Guido Vanham; Kevin K Arien; Oliver T Fackler; Bruno Verhasselt
Journal:  Retrovirology       Date:  2012-04-27       Impact factor: 4.602
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.